{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:44:32Z","timestamp":1773431072556,"version":"3.50.1"},"reference-count":20,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2016,3]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Despite the increasing prevalence of type 2 diabetes mellitus (T2DM<\/jats:styled-content>) in A<\/jats:styled-content>sia, clinical trials for glucose\u2010lowering therapies are often dominated by C<\/jats:styled-content>aucasian and\/or W<\/jats:styled-content>estern populations. The present Phase III<\/jats:styled-content> randomized placebo\u2010controlled double\u2010blind, 24\u2010week study evaluated the efficacy and safety of the dipeptidyl peptidase\u20104 inhibitor linagliptin added to metformin in A<\/jats:styled-content>sian T2DM<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>Methods<\/jats:title>In all, 306 patients (n<\/jats:italic>\u2009=\u2009265 C<\/jats:styled-content>hinese; n<\/jats:italic>\u2009=\u200924 M<\/jats:styled-content>alaysian; n<\/jats:italic>\u2009=\u200917 F<\/jats:styled-content>ilipino), aged 18\u201380 years with HbA1c<\/jats:styled-content> between \u22657.0 and \u226410.0% and on metformin therapy were randomized (2:1) to either linagliptin 5\u2009mg daily or placebo added to metformin. Antidiabetes drugs other than metformin were washed out prior to randomization. The primary endpoint was change in mean HbA1c<\/jats:styled-content> from baseline after 24 weeks.<\/jats:p><\/jats:sec>Results<\/jats:title>Baseline characteristics were well\u2010matched between the groups (overall mean [\u00b1SD<\/jats:styled-content>] HbA1c<\/jats:styled-content> 8.0\u2009\u00b1\u20090.8%). Adjusted mean (\u00b1SE<\/jats:styled-content>) HbA1c<\/jats:styled-content> decreased in the linagliptin and placebo groups by \u22120.66\u2009\u00b1\u20090.05 and \u22120.14\u2009\u00b1\u20090.07%, respectively (placebo\u2010corrected difference \u22120.52\u2009\u00b1\u20090.09%; 95% confidence interval [CI<\/jats:styled-content>] \u22120.70, \u22120.34; P<\/jats:italic>\u2009<\u20090.0001). In patients with baseline HbA1c \u22658.5%, the placebo\u2010corrected decrease in HbA1c<\/jats:styled-content> was \u22120.89\u2009\u00b1\u20090.17% (P<\/jats:italic>\u2009<\u20090.0001). Adverse events occurred in similar proportions in the linagliptin and placebo patients (27.3% and 28.0%, respectively) and few were considered drug\u2010related (2.4% and 0.0%, respectively). Hypoglycemia occurred in 1.0% of patients in both groups. Linagliptin therapy was weight neutral.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Linagliptin 5\u2009mg was efficacious and well tolerated over 24 weeks in A<\/jats:styled-content>sian patients with T2DM<\/jats:styled-content> inadequately controlled by metformin.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1753-0407.12284","type":"journal-article","created":{"date-parts":[[2015,3,6]],"date-time":"2015-03-06T13:26:01Z","timestamp":1425648361000},"page":"229-237","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of linagliptin in A<\/scp>sian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24\u2010week, randomized clinical trial"],"prefix":"10.1111","volume":"8","author":[{"given":"Weiqing","family":"Wang","sequence":"first","affiliation":[{"name":"Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinkui","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Tongren Hospital Capital Medical University Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gangyi","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gong","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma Ingelheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Bracknell UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Zhang","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International Trading Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyasu","family":"Izumoto","sequence":"additional","affiliation":[{"name":"Nippon Boehringer Ingelheim Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Ning","sequence":"additional","affiliation":[{"name":"Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2004.11.014"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.22558"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12098"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801043"},{"key":"e_1_2_8_6_1","unstructured":"International Diabetes Federation (IDF).IDF treatment algorithm for people with type 2 diabetes.2013. Available from:http:\/\/www.idf.org\/sites\/default\/files\/Type%202%20treatment%20algorithm.pdf(accessed 12 November 2013)."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/11630900-000000000-00000"},{"key":"e_1_2_8_9_1","unstructured":"Boehringer Ingelheim Ltd.Trajenta summary of product characteristics.2012. (updated 19 November 2012). Available from:http:\/\/www.medicines.org.uk\/emc\/medicine\/25000\/spc(accessed 3 March 2013)."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01350.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01391.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01326.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2011.03387.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.964856"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.805123"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60691-6"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2012.00213.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01593.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2011.07.035"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1684"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0706"}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1753-0407.12284","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.12284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T14:33:58Z","timestamp":1696257238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.12284"}},"subtitle":["\u5728\u4e8c\u7532\u53cc\u80cd\u6cbb\u7597\u8840\u7cd6\u63a7\u5236\u4e0d\u4f73\u7684\u4e9a\u6d322\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e2d\u5229\u683c\u5217\u6c40\u7684\u7597\u6548\u548c\u5b89\u5168\u6027:\u4e00\u9879\u4e3a\u671f24\u5468\u7684\u56fd\u9645\u591a\u4e2d\u5fc3\u968f\u673a\u4e34\u5e8a\u7814\u7a76"],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/1753-0407.12284"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.12284","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]},"assertion":[{"value":"2014-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}